When Susan Murray received an injection in Truro, Nova Scotia, on August 3, 2026, she became the first human volunteer in a clinical study that could alter the course of epidemic preparedness.
CEPI
The trial evaluates mRNA-1469, Moderna’s investigational messenger RNA vaccine candidate engineered specifically to prevent disease caused by the Bundibugyo ebolavirus. Following regulatory clearance from Health Canada, this Phase 1 study marks a critical step forward in addressing the explosive Ebola outbreak surging through the Democratic Republic of the Congo (DRC).
Newswire.com
With over 3,800 confirmed infections and more than 1,700 deaths recorded since mid-May, the current epidemic is already the second-largest Ebola outbreak in recorded human history. Because the World Health Organization (WHO) declared the crisis a Public Health Emergency of International Concern, international health coalitions have turned to advanced biotechnology to fill a glaring void: there are currently no licensed vaccines or approved antivirals anywhere in the world for the Bundibugyo strain.
CBC
+ 1
Supported by up to US $50 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Canadian trial represents a joint effort between global health funders, national regulators, and private enterprise.
Newswire.com
1. The Human and Epidemiological Reality in the DRC
To grasp the urgency driving the mRNA-1469 trial, it is vital to examine conditions on the ground in Central Africa.
┌──────────────────────────────────────────────┐
│ DEMOCRATIC REPUBLIC OF CONGO │
│ 2026 OUTBREAK SNAPSHOT │
└──────────────────────┬───────────────────────┘
│
┌────────────────────────────────┼────────────────────────────────┐
▼ ▼ ▼
[ 3,800+ Cases ] [ 1,700+ Deaths ] [ 0 Approved Vaccines ]
Rapidly expanding Mortality rate ~45% Ervebo ineffective vs.
in eastern provinces in remote areas Bundibugyo strain
Unlike the more famous Zaire strain—which can be contained using Merck’s licensed Ervebo vaccine—the Bundibugyo ebolavirus possesses a distinct surface glycoprotein sequence. Consequently, antibodies generated by existing vaccines do not provide neutralizing protection against Bundibugyo.
Epidemiologists note that cases in eastern Congo are rising faster than during the initial phases of the historical 2014–2016 West Africa epidemic. Healthcare teams navigating remote, conflict-affected regions face severe logistical barriers:
CEPI
Contact Tracing Obstacles: High population mobility and ongoing localized instability make isolating exposed individuals difficult.
Lack of Targeted Therapeutics: Clinicians are limited to supportive care (fluid rehydration, electrolyte balancing, and symptom relief).
Ring Vaccination Gaps: Without a protective vaccine against Bundibugyo, containment strategies rely entirely on quarantine and behavioral interventions.
As Dr. Richard Hatchett, CEO of CEPI, emphasized upon the launch of the trial: “Getting Moderna’s vaccine candidate into a Phase 1 trial this rapidly is a major step forward… Every day matters and every vaccine candidate in clinical trials gives us another shot at getting a safe, effective vaccine to the people who need it as swiftly as possible.”
CEPI
2. Trial Architecture: Evaluating mRNA-1469 in Canada
The Phase 1 study authorized by Health Canada is enrolling approximately 80 healthy adult participants across three specialized research hubs:
CEPI
Canadian Center for Vaccinology / IWK Health Centre (Halifax, Nova Scotia)
CBC
Truro Clinical Research Site (Truro, Nova Scotia)
CEPI
Toronto Phase 1 Clinical Site (Toronto, Ontario)
CBC
Clinical Objectives
The primary goals of the Phase 1 trial are to establish:
Safety & Reactogenicity Profiles: Determining tolerability across different dosage tiers to ensure minimal side effects.
Mirage News
Immunogenicity: Measuring antibody levels and T-cell responses generated against the synthetic Bundibugyo glycoprotein.
Optimal Dosing: Pinpointing the exact concentration required to elicit protective immune markers without provoking excessive systemic reactions.
┌─────────────────────────────────────────────────────────────────────────┐
│ SAFETY GUARANTEE PROTOCOL │
├─────────────────────────────────────────────────────────────────────────┤
│ • mRNA-1469 contains NO live virus, NO attenuated virus, and NO vector. │
│ • Participants receive synthetic mRNA encapsulated in lipids. │
│ • It is biologically IMPOSSIBLE to contract Ebola from the vaccine. │
└─────────────────────────────────────────────────────────────────────────┘
3. The Multi-Platform “Portfolio Strategy”
CEPI’s $50 million commitment to Moderna’s mRNA-1469 program is part of a broader portfolio approach to epidemic defense. Rather than relying on a single vaccine platform, CEPI is funding four distinct Bundibugyo candidate vaccines in parallel to maximize the probability of field success:
Newswire.com
+ 1
[ CEPI BUNDIBUGYO PORTFOLIO ]
│
┌───────────────────┬────────────────┴───────────────────┬───────────────────┐
▼ ▼ ▼ ▼
[ Moderna (mRNA-1469) ] [ Oxford (ChAdOx) ] [ IAVI / Hilleman ] [ Public Health Vaccines ]
Synthetic mRNA Viral Vector (ChAdOx) rVSV Platform rVSV Platform
Phase 1 (Canada) Phase 1 (UK) Preclinical/Trial Preclinical
Why a Multi-Platform Strategy Matters
Risk Mitigation: If one technological approach encounters unpredicted safety signals or manufacturing delays, alternative candidates remain in development.
Dose Availability: Scaling manufacturing across diverse supply networks (such as Hilleman Laboratories for rVSV constructs or Serum Institute of India for viral vectors) prevents bottlenecks.
CEPI
Storage Flexibility: While mRNA platforms excel in rapid sequence adaptability, viral-vector candidates may offer different cold-chain requirements in tropical field settings.
4. Solving the Access Equation: The 500,000-Dose Commitment
Historically, one of the greatest failures in global health has been the delay between scientific discovery in high-income nations and actual delivery to low- and middle-income countries (LMICs).
To ensure history does not repeat itself, the collaboration agreement between Moderna and CEPI incorporates explicit Equitable Access Provisions:
CEPI
Key Commitment: If mRNA-1469 proves safe and effective in clinical evaluation, Moderna has committed to supplying a minimum of 500,000 doses dedicated specifically for low- and middle-income countries at affordable access pricing.
CEPI
┌─────────────────────────────────────────────────────────────────────────┐
│ EQUITABLE ACCESS PIPELINE │
├─────────────────────────────────────────────────────────────────────────┤
│ 1. Early Manufacturing: Parallel dose production during early trials │
│ 2. Regulatory Pathway: Fast-track WHO Emergency Use Listing (EUL) │
│ 3. Allocation: Strategic deployment via GAVI & UNICEF procurement │
│ 4. Priority Pricing: Guaranteed non-profit / access-tier pricing │
└─────────────────────────────────────────────────────────────────────────┘
Furthermore, CEPI’s funding model actively supports parallel dose manufacturing during early clinical development. Instead of waiting for Phase 3 trials to complete before initiating large-scale production, industrial batches are manufactured concurrently. If efficacy targets are met, hundreds of thousands of doses will be available for field deployment without multi-month manufacturing delays.
Comparison: Global Epidemic Response Platforms
Feature Traditional Outbreak Response CEPI Accelerated Framework (mRNA-1469)
Funding Structure Reactive / Post-outbreak grants Proactive Portfolio Commitments ($50M)
Manufacturing Setup Sequential (Post-Phase 3) Parallel Scaling During Phase 1/2
Global Access Terms Negotiated post-approval Pre-negotiated 500k LMIC Dose Guarantee
Regulatory Strategy Standard multi-year pathway Streamlined Emergency Use / Extraordinary Use
Conclusion: A Benchmark for Pandemic Preparedness
The launch of the Phase 1 trial for mRNA-1469 in Halifax, Truro, and Toronto marks a pivotal point in the fight against filoviruses. By uniting Health Canada’s regulatory oversight, Moderna’s mRNA technology, CEPI’s financial backing, and clear health equity commitments, the international community is establishing a new standard for responding to neglected infectious threats.
CEPI
+ 1
As clinical researchers monitor the first cohort of volunteers in Canada, the ultimate goal remains clear: translating scientific breakthroughs in North American labs into life-saving protection for frontline workers and communities across Central Africa.
CEPI
